Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission
Status:
Completed
Trial end date:
2008-05-05
Target enrollment:
Participant gender:
Summary
To evaluate the long-term safety and tolerability of encapsulated mesalamine Granules (eMG)
(formerly referred to as Mesalamine Pellets [MP]) in participants with ulcerative colitis
currently in remission.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.